As a follow-up, Pyonteck et al. used another CSF-1R inhibitor, BLZ945, on a murine model of RCAS-human platelet-derived growth factor subunit B (hPDGF-B) induced gliomas, which resulted in significantly improved long-term survival rate of 64.3% and no detectable lesions in 55.6% of asymptomatic mice (84). This evidence concerns the gene CSF1R and central nervous system cancer.